BigChris16
5年前
“Immediately following the closing, Ritter will be renamed “Qualigen Therapeutics, Inc.,” and is expected to trade on The Nasdaq Capital Market on a post-reverse stock split basis under the new ticker symbol “QLGN” beginning on Tuesday, May 26, 2020.”
Does that mean our shares just turn into QLGN? Or do we have to do something?
rawsteel
5年前
RTTR on the way to the Nasdaq.
Pharmaceuticals (RTTR) said Tuesday its all-stock merger deal with Qualigen has received approval from Ritter stockholders and should be consummated in the next few days.
Under the agreement, pre-merger Ritter Pharmaceuticals stockholders will own approximately 7.5% of the post-merger combined company. On the other hand, the pre-merger Qualigen stockholders will own approximately 92.5% of the post-merger combined company on a fully-diluted basis.
Prior to closing, the company will change its name to Qualigen Therapeutics and continue trading on Nasdaq Capital Market under the symbol "QLGN."
Mergers and acquisitions (M&A) are forms of corporate restructuring that are becoming increasingly popular. The motive for wanting to merge with or acquire another company comes from management trying to achieve better synergy within the organization. This synergy is thought to increase the competitiveness and efficiency of the company. Mergers and acquisitions are also ways for a company to acquire capabilities it either cannot or does not want to develop internally, as well as to take over a company viewed as underperforming or undervalued and unlock value by changing operations or taking the company private.
Mergers usually occur on an all-stock basis. This means the shareholders of both merging companies are given the same value of shares in the new company that they owned in one of the old companies. Therefore, if a shareholder owned $10,000 worth of shares before the merger, he or she would own $10,000 in shares of the newly formed company after the merger. The number of shares owned would most likely change following the merger, but the value would remain the same.
rawsteel
5年前
We haven't tanked yet. That's a POSITIVE
Ritter Pharmaceuticals, Qualigen All-Stock Merger Deal Gets Shareholder OK
08:37 AM EDT, 05/19/2020 (MT Newswires) -- Ritter Pharmaceuticals (RTTR) said Tuesday its all-stock merger deal with Qualigen has received approval from Ritter stockholders and should be consummated in the next few days.
Under the agreement, pre-merger Ritter Pharmaceuticals stockholders will own approximately 7.5% of the post-merger combined company. On the other hand, the pre-merger Qualigen stockholders will own approximately 92.5% of the post-merger combined company on a fully-diluted basis.
Prior to closing, the company will change its name to Qualigen Therapeutics and continue trading on Nasdaq Capital Market under the symbol "QLGN."
On a side note they did say before"Ritter stockholders should also be aware that they will not be subject to a lock-up period following the merger.”
rawsteel
5年前
News out
LOS ANGELES , May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count certified by the inspector of election for the special meeting of stockholders held on May 18, 2020 , its stockholders approved all of the Qualigen, Inc. merger-related proposals, including: (i) the issuance of Ritter common stock and convertible preferred stock pursuant to the Agreement and Plan of Merger, dated as of January 15, 2020 , as amended, by and among Ritter, RPG28 Merger Sub, Inc. , and Qualigen, Inc. (“Qualigen”) and the change of control of Ritter resulting from the merger, (ii) a reverse stock split of the outstanding shares of common stock of the Company, at a ratio within a range of 1-for-25 to 1-for-35, as determined by the board of directors of the Company, (iii) changing the name of Ritter from “Ritter Pharmaceuticals, Inc.” to “Qualigen Therapeutics, Inc.” and (iv) the adoption of Ritter’s 2020 Equity Incentive Plan.
“We’d like to recognize our shareholders for their strong participation and overwhelming support of this transaction with Qualigen,” said Andrew J. Ritter . “We look forward to completing the merger with Qualigen , a transaction which we believe will create continued value for our shareholders.”
As previously announced, the boards of directors of both Ritter and Qualigen unanimously approved the merger, which is expected to be consummated in the next few days. In connection with the closing of the transaction, the Company will change its name to “Qualigen Therapeutics, Inc.” and the Company’s shares are expected to continue trading on The Nasdaq Capital Market under the symbol “QLGN”.